Dietary fat provides a major source of nutrition, but may in excess lead to obesity, insulin resistance, high blood cholesterol levels and atherosclerosis. Here we report molecular events that co-ordinate whole-body lipid homoeostasis from insects to humans, viewed in the context of rare and common genetic disorders of apolipoprotein B-containing lipoprotein production.
Introduction
The British diet provides around 35% of its energy in fat. These fats enter the luminal surface of the absorptive cell of the small intestine as lipolytic products, and emerge from the basolateral surface as CMs (chylomicrons). The catabolism of dietary lipids in CMs provides peripheral tissues with an important source of energy, which may be stored in times of nutritional abundance in fat depots. In the liver, the lipid moieties of CM catabolism (i.e. fatty acids and a cholesterolenriched remnant particle) are either further metabolized or re-packaged as VLDLs (very-low-density lipoproteins). Low-density lipoprotein, the product of VLDL catabolism, and the CM remnant particles of CM catabolism are the agents provocateur of atherosclerosis (see [1, 2] and references therein).
The mechanisms regulating the production of CMs and VLDL are important for survival in infancy and adulthood (Table 1 ). In the absence of VLDL and/or CM production, patients typically present within the first month of life with failure to thrive due to severe fat malabsorption. In adults, high production levels of CM and VLDL are associated with obesity, insulin resistance, mixed hyperlipidaemia and premature atherosclerotic cardiovascular disease (see [1, 2] and references therein).
ApoB (apolipoprotein B) [OMIM (Online Mendelian Inheritance in Man) 107730] is the major structural protein of both CMs and VLDL [3] . In humans, the small intestine produces the edited form of apoB mRNA that encodes apoB48, while the liver produces apoB100 [4] . ApoB48 comprises the first 2152 amino acid residues of the 4536-amino-acid apoB100 protein. In the currently accepted model of CM and VLDL assembly, apoB becomes associated with a neutral lipid load in two steps [5, 6] . The first involves the concurrent formation of an apoB-free lipid droplet and a lightly lipidated precursor apoB-containing lipoprotein. In the second step, the precursor CM and VLDL particle fuses with an apoB-free lipid droplet(s) to form a triacylglycerol-rich, apoB-containing lipoprotein, which may undergo further lipidation in the Golgi apparatus.
Abetalipoproteinaemia is caused by mutations of MTP (microsomal triacylglycerol transfer protein)
Abetalipoproteinaemia is a rare autosomal recessive disorder, characterized by a selective absence of apoB-containing lipoproteins in blood (OMIM 200100) [7] . The condition typically presents as failure to thrive in infancy due to severe fat malabsorption, or in older children as an atypical pigmented retinopathy associated with spinocerebellar degeneration. Early diagnoses combined with vitamin E supplementation help prevent the progression of the neuromuscular complications associated with this disease. Most mutations in abetalipopoproteinaemia encode a C-terminally truncated form of the 894-amino-acid MTP (OMIM 200100) [7] [8] [9] [10] [11] , suggesting that the C-terminal sequences of MTP serve an important structural and/or functional role.
MTP is a member of the large lipid transfer family of proteins that includes insect, nematode and vertebrate MTPs (http://www.ensembl.org), the vitellogenins and apoB [12, 13] . These proteins perform a diverse range of functions, and possess a highly conserved N-terminal domain (i.e. Interpro1747 domain) comprising some 600 amino acid residues. The C-terminal domains are highly variable in length, ranging from some 300 amino acid residues in the MTPs to nearly 4000 amino acids in apoB100, and have evolved to transport different amounts and types of lipids [1, 3, [13] [14] [15] .
MTP resides within the secretory pathways of hepatocytes and enterocytes, where it forms a heterodimer with the ER (endoplasmic reticulum)-chaperone-like protein, protein disulphide isomerase [14] . Protein disulphide isomerase may help to retain MTP at the site of apoB translocation, as it alone contains a KDEL ER-retention sequence. In the first step Clinically asymptomatic/premature coronary heart disease/part of metabolic syndrome X, mixed pattern of hyperlipidaemia in families of index patients
High fasting triacylglycerol and/or cholesterol, and/or apo B in blood [35, 37, 38, 40, 50] of the apoB-containing lipoprotein assembly process, MTP co-translationally loads apoB with lipid. This process is mediated by the highly conserved Interpro1747 domains of MTP and apoB, which interact in a head-to-head configuration as apoB is translocated into the ER [12, 16] . Three missense mutations have been identified in the Interpro1747 domains of apoB and MTP. The apoB mutation (R463W) causes the co-dominant disorder familial hypobetalipoproteinaemia in a large Christian Lebanese kindred [17] , whereas the MTP mutations (R540H, S590I) cause abetalipoproteinaemia [7, 11] . Shelness and colleagues have recently established that MTP is an ancient protein and that the Drosophila melanogaster homologue shares some, but not all, of the activities of the mammalian MTPs [13] . For example D. melanogaster MTP is able to support the lipidation of two C-terminally truncated forms of apoB (i.e. apoB34 and apoB41 on the percentile scale) in a heterologous cell system, despite displaying a remarkably low level of triacylglycerol transfer activity in vitro. This may relate to the different mechanisms underlying insect and vertebrate lipoprotein assembly (see [13] and references therein). The putative substrates (i.e. apolipophorin II/I) for insect MTPs are secreted from fat bodies as relatively lipid-poor high-density lipoprotein particles. The subsequent expansion of high-density lipoprotein particles to lowdensity lipoproteins occurs extracellularly using lipid efflux from fat body cytosol, and does not depend on a lipid pool within the secretory pathways of these animals. By contrast, vertebrate precursor apoB-containing lipoproteins accrue substantial amounts of lipid as they move through the secretory pathways of enterocytes and hepatocytes. Transgenic mice and MTP inhibitor studies suggest that high levels of MTP-mediated lipid-transfer activity promote the accretion of the lipid into the ER [18] [19] [20] .
MTP transfers lipid from a donor to acceptor membrane in vitro by way of a shuttle mechanism (see [14] and references therein). During this process a stable MTPlipid intermediate is formed, which may diffuse to an acceptor membrane to release the MTP-bound lipid. Kinetic studies have shown that MTP transfers neutral lipid and phospholipid at different rates (see [14] and references therein), which may indicate that the lipids are bound at different sites. We have suggested that MTP contains a lipidbinding cavity that is similar, albeit smaller, in structure to that found in the large lipid-transfer protein, lamprey vitellogenins [21] . In addition, that the slow transfer of some phospholipid moieties by MTP [14] may be attributable to an interaction(s) between phospholipid headgroups and specific amino acid side chains lining the MTP cavity [21] . Analogous interactions have been observed in crystalline lamprey lipovitellin, the proteolytic product of vitellogenins [22] .
We have used a combined molecular modelling and sitedirected mutagenesis approach to understand how MTP might extract neutral lipid, from its sites of synthesis in the membranes of the ER, for transfer to apoB or an acceptor membrane [21] . The data suggest that human MTP (in contrast with D. melanogaster MTP) forms a hydrophobic helical peptide at the entrance to its lipid binding cavity, which acts in concert with a second helix to secure lipid for transfer to its lipid binding pocket. The first helix interacts with a membrane in a manner similar to viral fusion peptides, and is necessary for the acquisition of neutral lipid. The second helix, which contains one of three abetalipoproteinaemia missense mutations [10] , is required for the transfer of these lipids to the binding cavity of MTP [21] .
CMRD (chylomicron-retention disease) and AD (Anderson disease) are caused by defects of Sar1b
CMRD (OMIM 246700), AD (OMIM 607689) and CMRD with the neuromuscular disorder Marinesco-Sjogren Syndrome (OMIM 607692) are all characterized by the selective absence of CM in blood (Table 1 ). In marked contrast to abetalipoproteinaemia or severe forms of hypobetalipoproteinaemia (OMIM 107730), patients with CMRD and AD assemble CMs normally, but these are retained intracellularly in large membrane-bound compartments. The distinction between CMRD and AD had been made on the basis of apparent differences between the partitioning of CMs and of lipid droplets between membrane-bound and cytosolic compartments. At the gene level, a series of different mutations within the SARA2 gene product (i.e. Sar1b) segregate with affected status in all patients [23] .
Sar1b is a member of the Sar1/Arf family of small GTPases that governs the intracellular trafficking of proteins in COP (coat protein)-vesicular structures. Sar1b shares 90% amino acid sequence identity with human Sar1a, compared with 60% sequence identity with the yeast homologue, Sar1p. The Sar1 proteins direct the assembly of COPII-coated vesicles on the cytosolic surface of the ER [24, 25] .
Eight different mutations within SARA2 have been identified in CMRD, AD and CMRD in two brothers with the Marinesco-Sjogren Syndrome [23] . The most severe mutation, which is predicted to stop the translation of Sar1b 34 amino acids into the 198-amino-acid protein, was identified in a compound heterozygote patient with CMRD. The second allele in this patient bore a missense mutation that affected a highly conserved residue found in all small GTPases. The most severe phenotype (i.e. CMRD in two brothers with the Marinesco-Sjogren Syndrome) was associated with a splice-site mutation. This is predicted to produce no stable Sar1b protein or a C-terminally truncated protein with no GTPase activity. In fact, all five missense mutations identified in CMRD and AD map to the GDP/ GTP-binding site of Sar1b, and are predicted to massively impair the binding of these nucleotides [23] . In yeast, mutations within the highly conserved guanine nucleotide binding site motif GXXXXG 37 KT 39 reduces GTP binding to <10% of wild-type values. This blocks the formation of COPII vesicles, and the ER becomes distended [26] .
The integral membrane protein Sec12 initiates the assembly of COPII-coated vesicles on the ER through the exchange of GDP on Sar1 for GTP [27] . Activated Sar1 (i.e. Sar1-GTP) increases the interaction of the Sar1 proteins with the lipids of the ER membrane, the formation of a pre-budding complex through the recruitment of Sec23 complexed to Sec24, and the capture of Sec13/31 heterodimers. These five coat components (i.e. Sar1, Sec23/24 and Sec13/31) form the basic machinery required for budding and sorting of cargo into COPII-coated vesicles [28] [29] [30] .
The disassembly of the COPII coat, which is essential for targeting of cargo to the ER-Golgi intermediate compartment, en route to the Golgi apparatus, is triggered by an increased rate of GTP hydrolysis on the Sar1 proteins [28, 30] . This is stimulated by Sec23 and enhanced a further 10-fold following the recruitment of Sec13/31 to the assembling vesicle. Importantly, all of the amino acid differences between Sar1a and Sar1b reside at some distance from the GTP/GDP-binding sites of these proteins, and the Sar1-Sec23 interface [23] . Thus differences in the intrinsic GTPase activity of Sar1b and Sar1a are unlikely to account for why CM transport within enterocytes is dependent on Sar1b.
At the RNA level, both human isoforms of Sar1 are expressed in the small intestine [23] . We have suggested that Sar1b might be required for the formation of large COPII vesicles, since CMs vastly exceed the size of typical COPII-coated vesicles. In vitro, Sar1 can induce the formation of large vesicular structures [31] . By analogy, Sar1b may provide the temporal constraints in enterocytes that facilitate the packaging of the precursor CM particle into a COPII vesicular structure for export from the ER prior to coat disassembly. Alternatively, the recruitment of a CM precursor into a COPII-coated vesicle may require a specific sequence on apoB on the luminal side of the ER to interact with an adapter molecule to engage the COPII transport machinery on the cytosolic surface of the ER, as is the case for at least some proteins destined for the ER-Golgi intermediate compartment (see [32] and references therein). Recent studies also suggest that specific amino acid sequence motifs on the COPII coat protein Sec24 may also provide the signal(s) for exporting CMs from the ER in COPII-coated vesicles [32] . We envisage that the study of COP-mediated CM transport through the secretory pathways of enterocytes will continue to provide important insights into the molecular events that ensure that dietary lipids and fat-soluble vitamins enter the bloodstream, where they provide an important source of nutrition for survival.
Multiple loci implicated in FCHL (familial combined hyperlipidaemia)
Combined hyperlipidaemia (i.e. high blood levels of cholesterol and triacylglycerol) is a common disorder characterized by a particularly pernicious lipid profile and increased risk of coronary heart disease [33] . The name FCHL was originally coined by Goldstein et al. to describe a pattern of lipid abnormalities in 47 Seattle extended pedigrees [34] , which has been subsequently observed in many datasets ( [35] [36] [37] [38] and references therein). The Seattle families were ascertained through survivors of myocardial infarction who had raised cholesterol and triacylglycerol levels. Families in which there was a predominance of elevated cholesterol or triacylglycerol levels were assigned to groups termed familial hypercholesterolaemia and hypertriglyceridaemia, respectively. Pedigrees with a mix of hypercholesterolaemia and hypertriglyceridaemia were said to have FCHL (OMIM 44250). Affected family members characteristically have elevated levels of both cholesterol and triacylglycerol. However, increased cholesterol or triacylglycerol levels are also frequently observed.
A major limitation in the study of FCHL has been the absence of a consensus on diagnostic criteria, in large part due to our ignorance about the basic biochemical defect, which may vary between families. Stable isotope studies have established a correlation between increased production of VLDL-apoB and serum triacylglycerol levels [39] , while metabolic studies have implicated defective catabolism of CMs and VLDL and insulin resistance ( [35] [36] [37] [38] and references therein). It has also been suggested that increased fluxes of non-esterified fatty acids from peripheral fat to the liver may drive the over-production of VLDL in this condition, consistent with results from cell biology experiments [39] . We and others [35] [36] [37] [38] 40] have therefore adopted genetic approaches to identify the aetiology of the lipid abnormalities in FCHL.
In white British FCHL families, we have provided compelling evidence that the 11p14.1-q12.1 chromosomal region contains a locus for the triacylglycerol component of this disorder in a substantial proportion of affected families [LOD (logarithm of odds) = 2.9 at 47.1 cM, P = 0.00014] [38] . This interval, which was originally detected in 18 extended Dutch families [35] , may also contain a quantitative locus trait for serum cholesterol levels (LOD = 2.0 at 3.2 cM, P = 0.0011). These results, and the criterion used to define FCHL affected status in the Dutch families (i.e. raised cholesterol or triacylglycerol levels), raise the issue of whether the 11p14.1-q12.1 genomic interval might contain separate susceptibility alleles for the different lipid abnormalities of FCHL. In future studies, we envisage that a combined linkage and linkage dis-equilibrium approach will lead to the identification of the genetic lesion(s) that underlie the 11p14.1-q12.1 linkage signal. This would be expected to increase the likelihood of cloning additional genes in this condition through ordered subset analyses, and allow the identification of the primary metabolic pathway(s) that are perturbed in FCHL and the associated metabolic syndrome of insulin resistance, which are together present in up to 50% of patients with atherosclerosis.
In conclusion, the study of rare lipoprotein production disorders has already provided important insights into some of the key molecular processes regulating whole body lipid homoeostasis from insects to humans. In the future, we hope to extend this information by identifying the major proteins that promote the intracellular trafficking of CMs and VLDL through enterocytes and hepatocytes, as well as identifying the genetic variation that contributes to the inheritance of the most common disorder of lipid transport in humans, FCHL. We believe that this information will be important for understanding the generic mechanisms regulating lipid transport and homoeostasis, and may also suggest new therapeutic targets for treating the lipid abnormalities that so commonly predispose to premature atherosclerotic cardiovascular disease.
